Clinical efficacy of bevacizumab for the treatment of serious peritumorous brain edema / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 1045-1048, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-506729
ABSTRACT
Objective:
To investigate the efficacy of bevacizumab on the treatment of serious peritumorous brain edema.Methods:
A total of 16 patients with malignant brain tumors and serious peritumorous brain edema, (13 cases of lung cancer, 2 cases of breast can-cer, and 1 case of recurrent glioblastoma) were analyzed. Treatment with glucocorticoids, osmotic dehydration, and other convention-al approaches were not effective for these patients. Bevacizumab was administered at a dose of 5 mg/kg at least once every three or four weeks. The Karnofsky performance score (KPS) and the changes in cerebral edema symptoms, such as cerebral edema volume, tu-mor volume, edema index (EI), and changes in magnetic resonance imaging (MRI) were compared before and after treatment. The t-test and least-significant difference method were used to compare treatment groups.Results:
All bevacizumab-treated patients had re-duced symptoms. The KPS after treatment was significantly higher than that before treatment (P<0.001). The cerebral edema vol-umes, tumor volumes, and EI of 16 patients were significantly decreased (P<0.05). Bevacizumab caused mild clinical side effects. Con-clusionPreliminary results showed that treatment of serious peritumorous brain edema with bevacizumab was safe and effective.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Clinical Oncology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS